Search results
Results from the WOW.Com Content Network
We must carefully weigh the pros and cons of a given company to decide whether or not its stock is worth the appointed risk. The key is to find the right balance between risk and 3 Reasons to Sell ...
Let's take a look at VIVUS (NAS: VVUS) , a biotechnology Examine its pros and cons, and decide whether it's possible upside outweighs its risks. Buy, Sell, or Hold: VIVUS
In this entry, David and Austin focus on VIVUS, which saw shares clobbered in July. Is it time to invest in this cutting-edge company on the cheap, or is the poor month a sign of further troubles ...
While one poor quarter can devastate a stock in the near term, it is still. Shares of up-and-coming biotech company VIVUS (NAS: VVUS) floundered last week after its initial sales of obesity drug ...
The pieces of the puzzle are starting to fall into place for VIVUS (NASDAQ: VVUS) and its potential blockbuster anti-obesity drug, Qsymia. The drug, which was approved by the Food and Drug ...
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking analyst upgrades and downgrades -- just ...
VIVUS gained approval from the Food and Drug Administration for its obesity drug Qsymia this summer, and its stock is up approximately 80% since the beginning of 2012. This has been a solid return ...
Shares of VIVUS were up 10.5% today, after news that sales were up for November for the company's obesity drug, Qsymia. This may suggest that some of the company's new marketing strategies for the ...